Note: You clicked on an external link, which has been disabled in order to keep your shopping session open.
|Tested species reactivity||Human|
|Host / Isotype||Mouse / IgG1, kappa|
|Immunogen||Ni-NTA purified truncated recombinant human APOA5 expressed in E. Coli strain BL21 (DE3).|
|Contains||0.1% sodium azide|
|Storage Conditions||-20° C, Avoid Freeze/Thaw Cycles|
|Tested Applications||Dilution *|
|Flow Cytometry (Flow)||3-5 µg/10^6 cells|
|Immunocytochemistry (ICC)||2 µg/ml|
|Immunofluorescence (IF)||2 µg/ml|
|Immunohistochemistry (IHC)||5 µg/ml|
|Immunohistochemistry (Paraffin) (IHC (P))||5 µg/ml|
|Western Blot (WB)||1:500-1:2000|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
The target sequence has 83% sequence homology with bovine, 79% sequence homology with rat and 78% sequence homology with mouse. This antibody is not recommended for ICC/IF applications.
Apolipoprotein A5 (ApoA5) is fast gaining attention as a key regulator of serum triglyceride concentrations. An ApoA5 mouse knock-out model produced an approximately four fold increase in serum triglycerides, whereas a knock-in model with human ApoA5 produced 50-70% lower concentrations of mouse serum triglycerides. In addition, peroxisome proliferator-activated receptor-4 (PPAR-alpha) agonists, which are used clinically to lower serum triglyceride concentrations, cause increased ApoA5 mRNA expression. Recently, it was demonstrated that ApoA5 is present in human serum detected by polyclonal antibodies against both the NH2 and COOH termini, although at much lower concentration than other apolipoproteins.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
apo-AV; ApoA5; apolipoprotein A-V precursor variant 3; regeneration-associated protein 3
APOA5; APOAV; RAP3; UNQ411/PRO773